Advanced search
1 file | 501.10 KB Add to list

Mechanism of action of clinically approved adjuvants

Bart Lambrecht (UGent) , Mirjam Kool (UGent) , Monique Willart (UGent) and Hamida Hammad (UGent)
Author
Organization
Abstract
Aluminum-containing adjuvants continue to be the most widely used adjuvants for human use. In the last year a major breakthrough has been the realization that alum adjuvant triggers an ancient pathway of innate recognition of crystals in monocytes and triggers them to become immunogenic dendritic cells, nature's adjuvant. This recognition can occur directly, via the triggering of the NALP3 inflammasome by alum crystals, or indirectly through release of the endogenous danger signal uric acid. It is also clear now that adjuvants trigger the stromal cells at the site of injection, leading to the necessary chemokines that attract the innate immune cells to the site of injection. How exactly these pathways interact remains to be determined.
Keywords
uric-acid, in vivo, nalp3 inflammasome, toll-like receptors, monophosphoryl-lipid-a, Inflammatory dendritic cells, aluminium-hydroxide adjuvant, immune-responses, t-cells, vaccine adjuvants

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 501.10 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lambrecht, Bart et al. “Mechanism of Action of Clinically Approved Adjuvants.” Current opinion in Immunology 21.1 (2009): 23–29. Print.
APA
Lambrecht, B., Kool, M., Willart, M., & Hammad, H. (2009). Mechanism of action of clinically approved adjuvants. Current opinion in Immunology, 21(1), 23–29.
Chicago author-date
Lambrecht, Bart, Mirjam Kool, Monique Willart, and Hamida Hammad. 2009. “Mechanism of Action of Clinically Approved Adjuvants.” Current Opinion in Immunology 21 (1): 23–29.
Chicago author-date (all authors)
Lambrecht, Bart, Mirjam Kool, Monique Willart, and Hamida Hammad. 2009. “Mechanism of Action of Clinically Approved Adjuvants.” Current Opinion in Immunology 21 (1): 23–29.
Vancouver
1.
Lambrecht B, Kool M, Willart M, Hammad H. Mechanism of action of clinically approved adjuvants. Current opinion in Immunology. London, UK: Current biology ltd; 2009;21(1):23–9.
IEEE
[1]
B. Lambrecht, M. Kool, M. Willart, and H. Hammad, “Mechanism of action of clinically approved adjuvants,” Current opinion in Immunology, vol. 21, no. 1, pp. 23–29, 2009.
@article{682621,
  abstract     = {Aluminum-containing adjuvants continue to be the most widely used adjuvants for human use. In the last year a major breakthrough has been the realization that alum adjuvant triggers an ancient pathway of innate recognition of crystals in monocytes and triggers them to become immunogenic dendritic cells, nature's adjuvant. This recognition can occur directly, via the triggering of the NALP3 inflammasome by alum crystals, or indirectly through release of the endogenous danger signal uric acid. It is also clear now that adjuvants trigger the stromal cells at the site of injection, leading to the necessary chemokines that attract the innate immune cells to the site of injection. How exactly these pathways interact remains to be determined.},
  author       = {Lambrecht, Bart and Kool, Mirjam and Willart, Monique and Hammad, Hamida},
  issn         = {0952-7915},
  journal      = {Current opinion in Immunology},
  keywords     = {uric-acid,in vivo,nalp3 inflammasome,toll-like receptors,monophosphoryl-lipid-a,Inflammatory dendritic cells,aluminium-hydroxide adjuvant,immune-responses,t-cells,vaccine adjuvants},
  language     = {eng},
  number       = {1},
  pages        = {23--29},
  publisher    = {Current biology ltd},
  title        = {Mechanism of action of clinically approved adjuvants},
  url          = {http://dx.doi.org/10.1016/j.coi.2009.01.004},
  volume       = {21},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: